IGES Institute GmbH.
InGef-Institute for Applied Health Research Berlin GmbH, Berlin.
J Glaucoma. 2024 Aug 1;33(8):549-558. doi: 10.1097/IJG.0000000000002420. Epub 2024 May 17.
Based on a large administrative database of German claims data, our study provides current estimates of the prevalence and incidence of primary open angle glaucoma (POAG) in Germany and describes selected outcomes for prevalent patients with POAG.
To estimate the prevalence and incidence of POAG in Germany, to describe the patient population in terms of comorbidity burden, routine care, and overall healthcare resource utilization (HCRU) and associated costs, and to describe treatment patterns over time in patients undergoing relevant laser procedures.
Based on anonymized German claims data, we carried out a retrospective, noninterventional study covering calendar years 2016-2021.
For the adult German population (≥18 y), we estimated a POAG 1-year prevalence of 1.70% and a 1-year incidence of 0.17% in 2018; both increased with age, peaking in 80- to 89-year-olds. Prevalence and incidence were lower in 2020 (1.65% and 0.16%, respectively), the first year of the SARS-CoV-2 pandemic. Most patients solely received topical treatment. Most surgically treated patients underwent laser trabeculoplasty, followed by laser iridotomy, trabeculectomy, and filtration operations with implant. In patients undergoing laser trabeculoplasty, the treatment regimen was nearly unchanged in the second year after, compared with 2 years before the procedure. Multimorbidity was commonly observed; 75.5% of patients had arterial hypertension and 50.0% had disorders of lipoprotein metabolism and other lipidemias, compared with 60.1% and 39.2%, respectively, in an age- and sex-matched control sample.
Our study provides insights into epidemiology and routine care of POAG in Germany and HCRU in prevalent patients. There was little change in treatment regimens in patients who underwent laser trabeculoplasty, 2 years after the procedure. Most patients were multimorbid highlighting the need for comprehensive care.
基于德国索赔数据的大型行政数据库,本研究提供了德国原发性开角型青光眼(POAG)的患病率和发病率的最新估计,并描述了 POAG 现有患者的选定结局。
估计德国 POAG 的患病率和发病率,描述患者人群的合并症负担、常规护理以及整体医疗资源利用(HCRU)和相关成本,并描述接受相关激光治疗的患者随时间的治疗模式。
基于匿名的德国索赔数据,我们开展了一项回顾性、非干预性研究,涵盖了 2016 年至 2021 年的日历年度。
对于成年德国人群(≥18 岁),我们估计 2018 年 POAG 的 1 年患病率为 1.70%,发病率为 0.17%;两者均随年龄增长而增加,在 80 至 89 岁年龄组达到峰值。2020 年(分别为 1.65%和 0.16%)患病率和发病率较低,这是 SARS-CoV-2 大流行的第一年。大多数患者仅接受局部治疗。大多数接受手术治疗的患者接受了激光小梁成形术,其次是激光虹膜切开术、小梁切除术和植入物滤过手术。在接受激光小梁成形术的患者中,与手术前 2 年相比,术后第 2 年的治疗方案几乎没有变化。常合并多种疾病;75.5%的患者患有高血压,50.0%的患者患有脂蛋白代谢紊乱和其他血脂异常,而在年龄和性别匹配的对照组中,这一比例分别为 60.1%和 39.2%。
本研究提供了德国 POAG 的流行病学和常规护理以及现有患者的 HCRU 方面的见解。接受激光小梁成形术的患者在手术后 2 年内治疗方案变化不大。大多数患者合并多种疾病,这突显了全面护理的必要性。